It Is Time for Patient-Reported Outcome Measures to Be Included in the Approval Process for Solid Organ Transplant Medications
- PMID: 36734821
- PMCID: PMC8638394
- DOI: 10.1681/ASN.2021081136
It Is Time for Patient-Reported Outcome Measures to Be Included in the Approval Process for Solid Organ Transplant Medications
Comment on
-
Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.J Am Soc Nephrol. 2021 Dec 1;32(12):3252-3264. doi: 10.1681/ASN.2021050628. Epub 2021 Dec 1. J Am Soc Nephrol. 2021. PMID: 34706967 Free PMC article. Clinical Trial.
References
-
- Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, et al. : Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 374: 333–343, 2016 - PubMed
-
- Cohen E, Formica RN, Batra RK: Side effect driven conversion to belatacept for kidney transplant recipients in a clinical setting. J Clin Exp Immunol. 5: 21–24, 2020
-
- Stegall MD, Troy Somerville K, Everly MJ, Mannon RB, Gaber AO, First MR, et al. : The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium’s position statement. Am J Transplant 19: 625–632, 2019 - PubMed
-
- Neri L, Dukes J, Brennan DC, Salvalaggio PR, Seelam S, Desiraju S, et al. : Impaired renal function is associated with worse self-reported outcomes after kidney transplantation. Qual Life Res 20: 1689–1698, 2011 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical